Small molecule · developed by Pharming Technologies B.V.
Napazimone (KL1333) is an oral agent given twice daily, with doses titrated to the maximum well tolerated dose. It is studied in primary mitochondrial disease and mitochondrial diseases.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07514338 | Phase 2 | Mitochondrial Diseases | Recruiting | PHAR |
| NCT05650229 | Phase 2 | Primary Mitochondrial Disease | Recruiting | PHAR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Mitochondrial DiseasesPrimary Mitochondrial Disease
Updated Oct 25, 2026. Something wrong or missing? Report it on the PHAR page.
See PHAR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PHAR catalysts and pipeline →